Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 238

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography

Open access
Koopmans, Klaas P., Neels, Oliver C., Kema, Ido P., Elsinga, Philip H., Sluiter, Wim J., Vanghillewe, Koen, Brouwers, Adrienne H., Jager, Pieter L., de Vries, Elisabeth G.E.·2008·Journal of Clinical Oncology

Abstract

Purpose: To evaluate and compare diagnostic sensitivity of positron emission tomography (PET) scanning in carcinoid and islet cell tumor patients with a serotonin and a catecholamine precursor as tracers. Patients and Methods: Carcinoid (n = 24) or pancreatic islet cell tumor (n = 23) patients with at least one lesion on conventional imaging including somatostatin receptor scintigraphy (SRS) and computed tomography (CT) scan underwent 11 C-5-hydroxytryptophan (11 C-5-HTP) PET and 6-[F-18]fluoro-L-dihydroxy-phenylalanin (18 F-DOPA) PET. PET findings were compared with a composite reference standard derived from all available imaging along with clinical and cytologic/histologic information. Results: In carcinoid tumor patients, per-patient analysis showed sensitivities for 11 C-5-HTP PET, 18 F-DOPA PET, SRS, and CT of 100%, 96%, 86%, 96%, respectively, and in islet cell tumors of 100%, 89%, 78%, 87%, respectively. In carcinoid patients, per-lesion analysis revealed sensitivities for 11 C-5-HTP PET, 11 C-5-HTP PET/CT, 18 F-DOPA PET, 18 F-DOPA PET/CT, SRS, SRS/CT, and CT alone of, respectively, 78%, 89%, 87%, 98%, 49%, 73%, and 63% and in islet cell tumors of 67%, 96%, 41%, 80%, 46%, 77%, and 68%, respectively. In all carcinoid patients 18 F-DOPA PET and 11 C-5-HTP PET detected more lesions than SRS (P < .001). 11 C-5-HTP PET was superior to 18 F-DOPA PET in islet cell tumors (P < .0001). In all cases, CT improved the sensitivity of the nuclear scans. Conclusion: 18 F-DOPA PET/CT is the optimal imaging modality for staging in carcinoid patients and 11 C-5-HTP PET/CT in islet cell tumor patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.15.1126

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 238

Metadata

Authors
Koopmans, K. P., Neels, O. C., Kema, I. P., Elsinga, P. H., Sluiter, W. J., Vanghillewe, K., Brouwers, A. H., Jager, P. L., & de Vries, E. G. E.
Venue
Journal of Clinical Oncology
Published
2008-03-20
Volume
26
Issue
9
Pages
1489-1495
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2133225431
Cited by
238
References
1
FWCI
17.08
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography. https://app.cochat.ai/papers/10.1200/jco.2007.15.1126
The paper
Koopmans, K. P., Neels, O. C., Kema, I. P., Elsinga, P. H., Sluiter, W. J., Vanghillewe, K., Brouwers, A. H., Jager, P. L., & de Vries, E. G. E. (2008). Improved Staging of Patients With Carcinoid and Islet Cell Tumors With 18F-Dihydroxy-Phenyl-Alanine and 11C-5-Hydroxy-Tryptophan Positron Emission Tomography. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.1126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.